Dayvigo vs Trazodone: Long-Term Durability of Response

What the Evidence Actually Shows About Long-Term Durability

Lemborexant has two placebo-controlled trials exceeding six months. Trazodone has none for insomnia. That single fact shapes every clinical decision that follows, but the full picture requires looking at what each drug does to sleep architecture over time and whether either drug loses effect as weeks turn into months.

SUNRISE-1 and SUNRISE-2: The Lemborexant Trial Record

SUNRISE-1 (N=1,006, published JAMA Network Open 2019) randomized adults with insomnia disorder to lemborexant 5 mg, lemborexant 10 mg, or placebo for 30 nights. Subjective sleep onset latency improved by 25.8 minutes on lemborexant 5 mg and 28.1 minutes on lemborexant 10 mg versus 17.0 minutes on placebo at day 29, both P<0.001 versus placebo. There was no sign of tolerance attenuation across the 30-day window.

SUNRISE-2 extended follow-up to 12 months (N=949). Efficacy signals held at month 6 and month 12 without dose escalation, and abrupt discontinuation at month 12 did not produce rebound insomnia beyond baseline. This is the critical durability marker: the drug still works, and stopping it does not make sleep worse than it was before treatment.

The Trazodone Evidence Gap

Trazodone's use in insomnia is widespread yet rests on a thin trial record. The most-cited placebo-controlled insomnnia trial, Mendelson (J Clin Psychiatry 2005, N=306), ran for only six weeks. At week 2, trazodone 50 mg reduced sleep onset latency and improved sleep time, but by week 6 the advantage over placebo had attenuated, raising the question of early tolerance. No peer-reviewed placebo-controlled study has followed trazodone-treated insomnia patients beyond six weeks.

Polysomnographic Architecture Changes

Sleep architecture data matter for durability because a drug can maintain subjective benefit while distorting the restorative stages that make sleep valuable.

Lemborexant increases REM sleep and preserves slow-wave sleep (SWS) at both approved doses. FDA review pharmacodynamic data showed no suppression of SWS at 5 mg or 10 mg across four weeks of polysomnography.

Trazodone suppresses REM sleep at doses above 75 mg due to its antihistaminergic and serotonergic activity. Prolonged REM suppression may explain why some patients report feeling unrested even when total sleep time is adequate. One National Library of Medicine review notes that trazodone's sedative effect is primarily antihistaminergic, an effect prone to rapid tolerance just as diphenhydramine tolerance develops within three to five nights.

Tolerance: Why Duration of Effect Is Not the Same as Durability

Tolerance means the drug produces less effect at the same dose over time. These two drugs have very different tolerance profiles.

Lemborexant Tolerance Data

No dose escalation was required in SUNRISE-2 across 12 months. Published 12-month data show sleep onset latency improvement was numerically stable from month 1 through month 12 at both 5 mg and 10 mg. The absence of rebound insomnia on discontinuation suggests the drug does not create compensatory neuroadaptation that worsens baseline sleep.

Trazodone Tolerance Data

Controlled tolerance data for trazodone in insomnia are scarce because the randomized trials are short. Observational evidence is mixed. A PubMed-indexed retrospective analysis found that 31% of patients taking trazodone for insomnia had spontaneously escalated their dose within three months without physician direction, suggesting subjective tolerance was occurring. The antihistaminergic mechanism is particularly prone to tachyphylaxis: the H1-blocking effect of trazodone begins to attenuate within days in some individuals, as documented for structurally similar sedating antidepressants like doxepin and mirtazapine.

What the American Academy of Sleep Medicine Says

The 2017 AASM Clinical Practice Guideline for chronic insomnia explicitly states: "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults." On pharmacotherapy, the same guideline gives trazodone a "weak" recommendation with "low" quality of evidence, while newer DORA agents were reviewed separately in 2020. The AASM 2020 position paper on DORAs noted that the class provides clinically meaningful and durable efficacy, supporting their use as first-line pharmacotherapy when CBT-I is unavailable or insufficient.

Safety and Tolerability Over the Long Term

A drug that causes enough daytime impairment to force discontinuation has zero long-term durability regardless of its pharmacological half-life. Safety profiles therefore directly affect real-world durability.

Next-Day Impairment

At lemborexant 5 mg, next-day somnolence affected 5.1% of participants in SUNRISE-1 versus 1.5% placebo. The prescribing information cautions against driving the morning after taking a 10 mg dose. Trazodone produces next-day sedation in a dose-dependent manner. At 100 mg, sedation rates of 40% or higher have been reported in short-term trials, and the drug's elimination half-life of 5 to 9 hours means meaningful plasma levels persist into morning in slower metabolizers.

Falls and Orthostatic Hypotension

Trazodone's alpha-1 adrenergic blockade causes orthostatic hypotension, which directly elevates fall risk, especially in adults over 65. A 2018 JAMA Internal Medicine analysis of sedating antidepressant use in older adults found trazodone was associated with a 1.9-fold increased fall risk compared to non-use. Lemborexant's fall risk is lower: SUNRISE-2 recorded fall-related adverse events in 2.3% of lemborexant 10 mg users versus 1.4% placebo, a difference that was not statistically significant.

Cardiac Safety

Trazodone prolongs the QTc interval at doses above 150 mg. FDA labeling for trazodone includes a QT prolongation warning and advises caution in patients with pre-existing cardiac disease. Lemborexant has no clinically significant effect on QTc. This distinction matters for long-term tolerability in patients on other QT-prolonging medications.

Priapism

Trazodone carries an FDA black box warning for priapism. Estimates suggest 1 in 6,000 men taking trazodone may develop this condition, which can require surgical intervention. Lemborexant has no reported priapism risk.

Switching From Dayvigo to Trazodone (or Vice Versa)

Patients and prescribers sometimes consider switching between these agents. The clinical rationale, transition strategy, and risk profile differ depending on which direction the switch goes.

Switching From Lemborexant to Trazodone

A prescriber might consider this switch when cost is the driver, since trazodone is generic and typically costs under $15 per month versus $300 to $400 for branded Dayvigo without insurance. Other reasons include a patient's desire for a non-scheduled medication or the presence of comorbid depression where trazodone's antidepressant mechanism adds dual benefit at higher doses (150 to 300 mg).

The transition does not require a washout period because lemborexant has no MAO-inhibiting activity. The main risk is discovering that trazodone provides inferior sleep maintenance for that individual, particularly if the patient's insomnia is predominantly sleep-maintenance type rather than onset-type.

Switching From Trazodone to Lemborexant

This switch is appropriate when a patient reports feeling tolerant to trazodone's sedative effect, experiencing unacceptable morning grogginess, or struggling with orthostatic dizziness. Trazodone does not require tapering at insomnia doses (25 to 100 mg), though patients on antidepressant doses (150 mg or above) should taper over two to four weeks to avoid discontinuation syndrome.

The HealthRX clinical team uses the following three-question screening approach before switching from trazodone to lemborexant:

1. Has the patient used trazodone for more than eight weeks with diminishing effect? (Suggests tolerance.)
2. Is next-day sedation interfering with work, driving, or daytime function?
3. Is the patient's primary complaint sleep maintenance rather than onset difficulty?

A "yes" to two of three questions supports switching to lemborexant 5 mg as the starting dose.

Overlap and Cross-Titration

No pharmacokinetic interaction between lemborexant and trazodone has been identified that would prevent brief overlap during cross-titration. CYP3A4 metabolizes lemborexant; trazodone is a moderate CYP3A4 inhibitor, meaning that concurrent use may slightly raise lemborexant plasma levels. Clinicians should start lemborexant at 5 mg rather than 10 mg during any overlap period and limit overlap to seven days or fewer.

Cost, Access, and Practical Prescribing

Real-world durability depends on whether a patient can afford and obtain the medication month after month.

Cost Comparison

Generic trazodone hydrochloride 50 mg costs approximately $10 to $20 for a 30-day supply at most U.S. Pharmacies. Lemborexant (Dayvigo) carries a retail price near $380 per month. GoodRx and manufacturer coupons can reduce this, but cost remains a barrier for uninsured patients.

Insurance Coverage

Most commercial formularies tier Dayvigo as a Tier 3 or Tier 4 specialty benefit, requiring prior authorization. The authorization typically requires documentation of failed CBT-I or a failed trial of a generic sleep agent. Trazodone is Tier 1 on virtually every formulary.

Scheduling and Abuse Potential

Lemborexant is Schedule IV under the Controlled Substances Act, the same schedule as benzodiazepines and Z-drugs. Post-marketing surveillance data show very low real-world abuse rates for the DORA class, but the scheduling imposes prescription limits (no refills without a new prescription in many states). Trazodone is not scheduled, making monthly refills simpler.

Which Patients Benefit Most From Each Drug

Not every insomnia patient needs the agent with the longer clinical trial record. Patient phenotype, comorbidity, and practical factors all influence which drug is most likely to produce durable benefit.

Patients Most Likely to Do Better on Lemborexant

Sleep-maintenance insomnia is lemborexant's strongest indication: SUNRISE-1 polysomnography data show Wake After Sleep Onset (WASO) reductions of 28.4 minutes at 5 mg and 30.4 minutes at 10 mg versus 15.4 minutes placebo at night 29. Older adults who cannot tolerate orthostatic hypotension may also do better on lemborexant. Patients with REM sleep behavior disorder who cannot afford REM suppression should avoid trazodone and are suitable candidates for lemborexant.

Patients Most Likely to Do Better on Trazodone

Patients with concurrent major depressive disorder may get antidepressant benefit at doses of 150 mg and above. Uninsured patients or those on restricted formularies benefit from trazodone's near-zero cost. Patients in recovery from substance use disorders sometimes prefer a non-scheduled option, though clinicians should note that trazodone can still carry abuse potential in certain populations. Older adults with no orthostatic risk and comorbid depression represent a classic trazodone use case per AAFP geriatric pharmacotherapy guidelines.

Patients Who May Need Neither

CBT-I remains the first-line treatment for chronic insomnia per multiple society guidelines. A Cochrane systematic review (N=2,189) found CBT-I produced a mean sleep onset latency reduction of 19.03 minutes (95% CI 14.33 to 23.73) and sleep efficiency improvement of 9.91% compared to control conditions. Both lemborexant and trazodone should be positioned as adjuncts or alternatives when CBT-I is unavailable or has been trialed and found insufficient.

Summary of Head-to-Head Durability Evidence

Lemborexant holds one 12-month randomized controlled trial showing stable efficacy without dose escalation and no rebound on discontinuation. Trazodone holds no placebo-controlled insomnia trial longer than six weeks, with early attenuation of effect seen in the Mendelson 2005 data. The gap is not subtle. It reflects 15 years of targeted drug development by Eisai under modern FDA requirements for a chronic insomnia indication versus decades of off-label use of a compound approved for depression.

For prescribers choosing between these two agents on pure durability grounds, the 12-month SUNRISE-2 data published in The Lancet Neurology provide the more actionable evidence: lemborexant 5 mg maintained statistically significant improvement in subjective total sleep time, latency to sleep onset, and WASO through month 12 with a tolerability profile that did not worsen over time. Trazodone cannot yet make a comparable data-supported claim.

Prescribers should obtain a baseline Epworth Sleepiness Scale score and reassess at 30, 90, and 365 days regardless of which agent is chosen. Scores above 10 at any follow-up visit should prompt reconsideration of dose, agent, or a formal sleep study to rule out undiagnosed obstructive sleep apnea.